Xvivo Perfusion AB (publ) (XVIVO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much. Good morning and good afternoon. And most of all, welcome to Exvivo's earning call for the fourth quarter, as well as for the full year of 2025. And with that, we turn over to slide two. It's just the two presenters that were introduced. It's me, Kristoffer Rosenblatt, calling in from Gothenburg, and the company CFO, Kristoffer Nordstrom, calling in from Philly in the United States. And with that, we can go over to slide three, which are the Q4 financial at the glance. The Q4 shows 10% organic top line growth, which is equivalent to a 12% top line organic growth if we adjust for the US heart trial revenue compared to Q4 last year. With recovering sales, the EBITDA recovered to healthy levels during Q4. Again, showing that the revenue model is scalable. In terms of segment growth, the track sales were slightly negatively affected by the lower hard study revenue compared to same quarter last year in the United States, but positively affected by a stronger Q4 long market. It's especially stronger if you compare sequentially to Q3 this year, and even more so if you compare to Q2 this year. The abdominal segment shows great progress for both liver and kidney during the quarter. As stated earlier, liver in Europe has entered the majority market segment with penetration about 50% in many countries and up to 25% in core markets. The main task is to support growth with increasing resources for perfusion as well as more data for improved reimbursement level. In parallel, we are increasing the sales force footprint in Europe. While kidney on the other hand is still below 15% penetration in many countries, including the US, the main task is to win account by account. We are very, very encouraged by the positive feedback we get from our kidney customers. They s...